Purdue Pharma L.P. has entered into an agreement to have its pipeline medication tinostamustine included in the Phase 2/3 GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) adaptive clinical trial for glioblastoma patients led by the Global Coalition for Adaptive Research (GCAR).
Health Technology Insights: MY DR NOW Opens New Clinic in Queen Creek
Tinostamustine is a first-in-class, new chemical entity that combines two potentially synergistic mechanisms of action, bifunctional alkylating activity and pan histone deacetylase inhibition (or HDAC inhibition). Tinostamustine is under investigation in patients with glioblastoma, an aggressive brain cancer that is very challenging to treat and for which there is no cure. Most patients do not survive more than 15 months with current treatment approaches. Tinostamustine has the potential to be a first-line treatment. Nearly 14,000 people in the U.S. are diagnosed with glioblastoma each year. Tinostamustine will be investigated in patients with newly diagnosed glioblastoma as an adjuvant therapy following standard treatment with surgery, chemotherapy and radiation, as well as in patients with recurrent disease.
Health Technology Insights: HOYA Launches VisuPro Lenses for Early Presbyopia Support
GBM AGILE is a pioneering, international adaptive platform trial designed to accelerate the identification of effective treatments for glioblastoma. It is led by GCAR, a non-profit corporation, and is supported by a global network of oncologists, neuro-oncologists, clinicians, researchers, biostatisticians, and patient advocates. Unlike traditional trials, GBM AGILE offers a seamless phase 2/3 design that supports a well-defined path for FDA registration. It allows for the simultaneous assessment of multiple investigational therapies against a common control arm, significantly reducing development time by adapting to emerging data and prioritizing promising new treatments.
“We are pleased to partner with GCAR in GBM AGILE to further study tinostamustine, which has shown promise in early trials,” said Dr. Julie Ducharme, Vice President and Chief Scientific Officer, Purdue. “GBM AGILE accelerates the clinical trial timeline to speed medicines to patients, which aligns with our mission to address serious, unmet medical needs.”
“We are pleased to be evaluating tinostamustine in GBM AGILE,” said Dr. Meredith Buxton, Chief Executive Officer/President, GCAR. “Glioblastoma is the deadliest brain cancer, and our mission is to find promising new treatments to improve overall survival as compared to standard treatments. We are now hard at work collaborating on the Investigational New Drug Application (IND) and Clinical Trial Application (CTA) submissions necessary to include tinostamustine in our innovative and patient-centric adaptive trial.”
The study is anticipated to begin following IND submission and FDA approval of the protocol with activation in Canada, Europe, and Australia to follow.
*Tinostamustine is an investigational agent. This announcement discusses its use in clinical development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that tinostamustine will successfully complete development or receive regulatory approval.
Health Technology Insights: University Lab Partners and BARDA Launches ReadyDetect: A $10 Million Competition For Diagnostics
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
